Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA046496-01
Application #
3549057
Study Section
(SRC)
Project Start
1987-09-08
Project End
1988-08-31
Budget Start
1987-09-08
Budget End
1988-08-31
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
University of Pennsylvania
Department
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Armstrong, William B; Taylor, Thomas H; Meyskens, Frank L (2005) Can a marker be a surrogate for development of cancer, and would we know it if it exists? Recent Results Cancer Res 166:99-112
Armstrong, William B; Taylor, Thomas H; Meyskens Jr, Frank L (2003) Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12:589-92
Kennedy, Ann R; Kritchevsky, David; Shen, Wei-Chiang (2003) Effects of spermine-conjugated Bowman-Birk inhibitor (spermine-BBI) on carcinogenesis and cholesterol biosynthesis in mice. Pharm Res 20:1908-10
Armstrong, William B; Wan, X Steven; Kennedy, Ann R et al. (2003) Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope 113:1687-702
Kennedy, Ann R; Billings, Paul C; Wan, X Steven et al. (2002) Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr Cancer 43:174-86
Armstrong, W B; Kennedy, A R; Wan, X S et al. (2000) Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9:43-7
Wan, X S; Lu, L J; Anderson, K E et al. (2000) Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay. Cancer Epidemiol Biomarkers Prev 9:741-7
Armstrong, W B; Kennedy, A R; Wan, X S et al. (2000) Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6:4684-91
Kennedy, A R (1998) The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68:1406S-1412S
Hawkins, J V; Emmel, E L; Feuer, J J et al. (1997) Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 42:1969-80

Showing the most recent 10 out of 43 publications